Search results
Results From The WOW.Com Content Network
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
March 25, 2024 at 7:23 AM. (Reuters) -Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma on concerns over the ...
"Regeneron had a strong quarter, with total revenue up 12% driven by notable growth for EYLEA HD, Dupixent, and Libtayo," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron.
George D. Yancopoulos (born 1959) is a Greek - American biomedical scientist who is the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals. [1] Yancopoulos is the holder of more than 100 patents. [2] He is a principal inventor and developer of Regeneron's ten FDA -approved or -authorized treatments, as well as of ...
The arrows point from N- to C-terminus. Bi-specific T-cell engagers ( BiTEs) are a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells ' cytotoxic activity, against cancer cells.
Aflibercept. Aflibercept, sold under the brand names Eylea among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [10] [11] It was developed by Regeneron Pharmaceuticals . It is an inhibitor of vascular endothelial growth factor (VEGF). [12] [13]
Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's ...
The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs. U.S. sales ...